Hydrocortisone in Severe Community-Acquired Pneumonia.

BACKGROUND Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear. METHODS In this phase 3, multicenter, double-blind, randomized, controlled trial, we assigned adults who had been admitted to the intensive care unit (ICU) for severe community-acquired pneumonia to receive intravenous hydrocortisone (200 mg daily for either 4 or 8 days as determined by clinical improvement, followed by tapering for a total of 8 or 14 days) or to receive placebo. All the patients received standard therapy, including antibiotics and supportive care. The primary outcome was death at 28 days. RESULTS A total of 800 patients had undergone randomization when the trial was stopped after the second planned interim analysis. Data from 795 patients were analyzed. By day 28, death had occurred in 25 of 400 patients (6.2%; 95% confidence interval [CI], 3.9 to 8.6) in the hydrocortisone group and in 47 of 395 patients (11.9%; 95% CI, 8.7 to 15.1) in the placebo group (absolute difference, -5.6 percentage points; 95% CI, -9.6 to -1.7; P = 0.006). Among the patients who were not undergoing mechanical ventilation at baseline, endotracheal intubation was performed in 40 of 222 (18.0%) in the hydrocortisone group and in 65 of 220 (29.5%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.40 to 0.86). Among the patients who were not receiving vasopressors at baseline, such therapy was initiated by day 28 in 55 of 359 (15.3%) of the hydrocortisone group and in 86 of 344 (25.0%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.43 to 0.82). The frequencies of hospital-acquired infections and gastrointestinal bleeding were similar in the two groups; patients in the hydrocortisone group received higher daily doses of insulin during the first week of treatment. CONCLUSIONS Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. (Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.).

[1]  Grant D. Huang,et al.  Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia , 2022, Intensive Care Medicine.

[2]  W. Bos,et al.  Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial , 2021, European Respiratory Journal.

[3]  S. Peters,et al.  Sex differences in response to adjunctive corticosteroid treatment for patients with septic shock , 2021, Intensive Care Medicine.

[4]  D. Annane,et al.  Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[5]  Sarah Zohar,et al.  Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience , 2020, Statistics in biopharmaceutical research.

[6]  R. Cavallazzi,et al.  The Burden of Community-Acquired Pneumonia Requiring Admission to an Intensive Care Unit in the United States. , 2020, Chest.

[7]  F. Blasi,et al.  Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia , 2018, European Respiratory Journal.

[8]  W. Boersma,et al.  Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  William A. Mattingly,et al.  Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Anzueto,et al.  Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. , 2015, JAMA.

[11]  Q. Xiu,et al.  Corticosteroids in the Treatment of Community-Acquired Pneumonia in Adults: A Meta-Analysis , 2012, PloS one.

[12]  J. Dorca,et al.  Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial , 2011, Critical care.

[13]  T. Welte,et al.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality , 2009, Thorax.

[14]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[15]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[16]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.